Clinical Trial Update: Promitil Treatment of Patients With Solid Tumors Associated With Deleterious Mutations Who Have Progressed After Therapy [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating Promitil in patients with solid tumors carrying deleterious mutations that progressed after prior therapy has been terminated,…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ovarian Cancer
• Pancreatic Ductal Adenocarcinoma

Drugs mentioned

• Promitil

Snippet

Sponsor: Lipomedix Pharmaceuticals Inc. | Conditions: Cancer of Ovary, Pancreatic Ductal Adenocarcinoma | Phase 2 | Status: TERMINATED